-
Bortezomib, sold
under the
brand name
Velcade among others, is an anti-cancer
medication used to
treat multiple myeloma and
mantle cell lymphoma. This...
-
improved outcomes with new
chemotherapy regimens, e.g., with
bortezomib.
Treatment with
bortezomib, melphalan, and
prednisone had an
estimated overall survival...
-
Bortezomib/dexamethasone is a
combination drug
against multiple myeloma. When
bortezomib is used by the
trade name Velcade, the
combination is
called Vel/Dex...
- been
exploited in
several recently developed chemotherapy agents such as
bortezomib and
salinosporamide A. In
response to
cellular stresses – such as infection...
- (Thal-dex), lenalidomide,
bortezomib (Velcade, Vel-dex), or a
combination of
doxorubicin (Adriamycin) and
vincristine or
bortezomib/lenalidomide/dexamethasone...
- have
received at
least two
prior therapies,
including treatment with
bortezomib and an
immunomodulatory therapy (such as lenalidomide) and have demonstrated...
- the drug
combinations of
lenalidomide plus
dexamethasone and
continuous bortezomib plus
lenalidomide plus
dexamethasone probably increased overall survival...
-
inhibitors are
being studied for the
treatment of cancer.
Drugs such as
bortezomib, carfilzomib, and
ixazomib are
already approved for use in
treating multiple...
-
December 2020,
selinexor was
approved by the FDA in
combination with
bortezomib and
dexamethasone for the
treatment of
adults with
multiple myeloma who...
-
include bortezomib-based treatment, an
autologous stem cell transplant, and if the
patient is
considered eligible, an
organ transplant.
Bortezomib is frequently...
